Established in 1970, the Inflammation Research Association is almost 50 years old! Back then research was focused on steroids and other general immune suppressors to treat a variety of inflammatory disorders, and today we have all witnessed the explosion in the use of biologic therapies that exquisitely target key inflammatory players. Yet general immune suppression remains a mainstay in the treatment of inflammatory conditions. Much like this research, our organization remains true to our original goals but continues to grow and change with the times.

Simply stated, the IRA is committed to bringing together academic, government, and pharmaceutical scientists to discover new therapies that treat a wide range of inflammatory diseases. We organize international and world congress meetings focused on cutting edge topics in inflammation. These conferences combine both basic research AND drug development, which makes us stand out against the many conferences that focus on one area or the other. The IRA is also committed to establishing a strong network of colleagues that can share ideas and help each other when entering the workforce or searching for new job opportunities - providing, for example a Job Board on our website and New Investigator Poster/Presentation and mentoring sessions at our meetings to guide new scientists on their career path.

While our commitment to organizing quality scientific meetings and dedication to growing and establishing our network of colleagues has not waivered, we will continue to move with the times and initiate new activities. Our website and social media content has expanded and the IRA Job Board is now active on our website so please check it out and send in your postings. (president@inflammationresearch.org). We have also forged new collaborative relationships with The New York Academy of Sciences and The Society of Leukocyte Biology and are sponsoring sessions and advertising each other’s conferences. These new initiatives and the increasingly difficult task of funding raising to support our continued success as a society requires tireless and dedicated volunteers. Please get involved!

Inflammation is a central player in many diseases and that is why we as Inflammation Research Association scientists keep focusing on understanding the complexities of inflammatory pathways. We believe taming these pathways is the key in developing future successful treatments for numerous patients. I ask that those of you that are involved stay involved, and also bring in new members to experience and share in the growth and successes of this organization.

Sincerely yours,

Lisa Schopf, PhD
President
Inflammation Research Association
President@inflammationresearch.org
International Meeting

20th International meeting of the Inflammation Research Association
July 20-21, 2018 | Philadelphia, PA

Plenary Sessions:
- Non-resolving inflammation in chronic diseases
- Intervention of systems inflammation and chronic diseases

Concurrent sessions *:
- Cellular and molecular mechanisms for inflammation
- Metabolic alteration in chronic inflammation
- Microbiome in systems inflammation
- Systems inflammation and intervention
- New therapy for chronic inflammation
- Junior investigator session

* All concurrent session speakers will be selected from submitted abstracts.

As a member of the Inflammation Research Association, you will be part of a large and supportive network and community. Membership provides discounted registration fees for IRA hosted meetings, access to the interactive jobs board, and interactions with scientists at the cutting edge of science in the broad field of inflammation. The IRA is your association, member-managed and member-driven, and we encourage you to take full advantage of benefits as a member in connecting with your peers to exchange key information for your career advancement, your research program and your expertise & knowledge base.

[www.inflammationresearch.org/member-login-renew/](http://www.inflammationresearch.org/member-login-renew/)

**People on the Move**

**Lisa Schopf**, IRA President, has joined Pfizer in Cambridge, MA, as Research Project Lead in Inflammation and Immunology. Email Lisa using Lisa.Schopf@pfizer.com

**Joel Tocker**, immediate IRA-Past President, accepted a new position as Executive Director at Crown Bioscience in San Diego where he will be building an autoimmune and inflammatory disease group. Contact Joel at jtocker@crownbio.com

**Matthew Sleeman**, IRA Board Member, is Executive Director, Immunology & Inflammation at Regeneron Pharmaceuticals in Tarrytown, NY. Use Matthew.sleeman@regeneron.com to message Matt

**Michael McQueney**, IRA Secretary, is Managing Director of Oncoveda Cancer Research Center in Hamilton, NJ. Mike's email is mmcqueney@oncoveda.com
officers and directors
2016 - 2018 term of the IRA

Officers

President
Lisa Schopf, PhD
Pfizer, Inc.
president@inflammationresearchassociation.org

Vice President
Liwu Li, PhD
Virginia Polytechnic Institute
vicepresident@inflammationresearchassociation.org

Secretary
Michael S. McQueney, PhD
Oncoveda Cancer Research Center
secretary@inflammationresearchassociation.org

Treasurer
Caralee Schaefer, PhD
Blade Therapeutics
treasurer@inflammationresearchassociation.org

Past President
Joel E. Tocker, PhD.
Crown Biosciences

Directors

Alison Budelsky, PhD
Janssen Research & Development LLC

Subba R. Chintalacharuvu, Ph.D., MBA
Covance

Anne M. Fourie, PhD
Janssen Research & Development LLC

Howard Kartstein
Metabolon, Inc.

Erik Lubberts, PhD
Erasmus MC, Univ. Medical Center

Alison O’Mahony, PhD
BioSeek, a division of DiscoverRx

Matthew A. Sleeman, PhD
Regeneron Pharmaceuticals

Dirk Smith, MSc.
Insight BioConsulting

Thomas A. Wynn, PhD
National Institutes of Health
2017 Autumn Regional Meeting of the Inflammation Research Association
Modulating Inflammation for the Treatment of Disease: Novel Therapeutic Approaches and Modalities

A one-day scientific conference sponsored by the Inflammation Research Association

**Conference theme:** Inflammation is a central physiologic process that contributes to tissue homeostasis, immunity, chronic disease and immunologic response to cancer. Therefore, novel therapeutic approaches to modulating inflammation hold great promise across many aspects of health and disease. This one-day meeting is focused on bringing together academic and industry scientists to share new ideas and science relevant to this topic. Participants will hear about new targets, new approaches to targeting or harnessing inflammation and novel modalities and drug engineering, such as bispecific antibodies and other drug scaffolds.

**Confirmed speakers:**
- Mike Wittekind, CEO, Olympic Protein Technologies
- John Babcook, Senior VP, Zymeworks, Inc.
- Wei Yan, CEO, Sound Biologics
- Chris Mehlin, Director, Peptide Drug Discovery, Fred Hutch
- Fred Ramsdell, VP, Research, Parker Institute for Cancer Immunotherapy
- Santanu Bose, Professor, Washington State University
- Gabriela Hoyos, Leader of Immunobiology Group, Aptevo
- Steven Ziegler, Director, Benaroya Research Institute
- Lili Cheng, Senior Scientist I, Protagonist Therapeutics

**Cost:**
- IRA members: $100*
- non-members: $200

*Save money today! Membership in the IRA is only $60. Become a member or renew your membership now: [http://www.inflammationresearch.org/join/](http://www.inflammationresearch.org/join/)

**Register Online:**
[Click](#) to register

The 2017 Autumn Regional Meeting will be held at the Bell Harbor International Conference Center in Seattle, WA, featuring 180-degree views of the Olympic Mountains, Mt. Rainier, Puget Sound’s Elliott Bay and the Seattle skyline.

For directions and lodging info please see: [www.bellharbor.com](http://www.bellharbor.com)

Click [here](#) for parking instructions at Bell Harbor.

Questions? Email Dirk Smith, co-organizer: [smith@thecddg.com](mailto:smith@thecddg.com)

**Posters, Abstracts and Meeting Agendas**

All participants are welcome to submit posters.

To submit an abstract, click [here](#) for the Abstract Submission Template. Full instructions are included.

[Click](#) for the complete meeting agenda

**Date:** October 13, 2017. 8:30-4:30